Photo - BioSapien Inc.
play_arrow
View
58480

BioSapien Inc.

USA, California
Market: Medicine, Pharmacology
Stage of the project: Idea or something is already done

Date of last change: 08.09.2022
Go to the owner's profile
2
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

BioSapien has developed a 3D printed biodegradable product that delivers FDA-approved chemotherapy drugs locally to cancerous cells. This novel drug delivery platform technology is called MediChip™.

Current Status

BioSapien’s lead product is a 3D printed biodegradable drug delivery platform that delivers FDA-approved chemotherapy drugs directly to cancerous cells. This novel technology is called MediChip™. This extended release dosage form provides a localized and sustained release of active pharmaceutical ingredients, The initial therapeutic agent is FDA approved 5-FU for locally advanced GI cancers. Future assets and further MediChip™ programs are focused on immuno-oncology agents and cell therapies. We have had great interest from centers of excellence in the oncology space across the US.

Problem or Opportunity

Systemic (IV) chemotherapy has been a major part of cancer care since the 1960s. Even for localized solid tumors, we poison the entire body to destroy this local tissue. We think it is time to change this model.

Solution (product or service)

BioSapien has developed a localized drug delivery platform that is designed to carry one or more active therapeutic agents. The intention is to reduce serious systemic side effects and to increase local penetration of the selected active agents. With a goal to improve patient outcomes and access to care, while reducing hospital and insurance burden.

Business model

Our focus is on the high unmet medical need applications in the lower GI oncology to start. Other potential indications include gastric, pancreatic, lung, esophageal, pyloric cancers. The MediChip™ is a drug delivery platform and not restricted to the oncology space. However we believe it could have the greatest impact and the shortest course to market through this avenue.

Incubation/Acceleration programs accomplishment

ELab NYC
SOSV IndieBio
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility406
star0
Add to favorites
Delete from favorites
share
close
thumb_up1
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video
Presentation